NIPT has never performed better
>99.9%
Accuracy for T21, T18, T13
26
Hours
98.8%
First Pass Success
Superior performance. More confidence.
It’s time to change the way you think about prenatal testing. The VeriSeq NIPT Solution v2 offers superior performance to any in vitro diagnostic (IVD) noninvasive prenatal testing (NIPT) solution available. With a sensitivity and specificity of >99.9% for trisomies 21, 18, and 13, a start-to-finish run time of just 26 hours, and a low sample failure rate, you can feel the confidence that comes with superior performance.
Beyond performance, VeriSeq NIPT Solution v2 also offers coverage across the entire fetal genome, with the option to screen for aneuploidy for all chromosomes and partial duplications and deletions of 7 Mb or higher for all autosomes. Most NIPTs only give information on the status of common aneuploidies of chromosomes 21, 18, and 13. You may be missing something if you’re not looking genome-wide.
Solution
1 Solution
The PCR-free, automated and validated workflow is CE-marked and fully integrated from sample prep to NextSeq 550Dx Sequencing System to assay software. With a comprehensive IVD solution, you have everything you need for NIPT using NGS. Watch how the VeriSeq NIPT Solution can take you from sample to results with an automated end-to-end workflow.
View Video
Additional Resources
The Clinical Value of NIPT
Learn how noninvasive prenatal testing (NIPT) is making an impact around the world.
VeriSeq NIPT Solution v2 Data Sheet
Get information on the reagents, instruments, and CE-IVD marked library prep, sequencing system, and analysis software for in-lab prenatal screening.
NIPT Technology Guide
Learn more about NIPT and key considerations when selecting a technology for screening with NIPT.
Understanding the VeriSeq NIPT Solution Assay
Dive into the VeriSeq NIPT assay and learn how it works.
Intended Use
The VeriSeq NIPT Solution v2 is an in vitro diagnostic test intended for use as a screening test for the detection of genome-wide fetal genetic anomalies from maternal peripheral whole blood specimens in pregnant women of at least 10 weeks gestation. VeriSeq NIPT v2 uses whole-genome sequencing to detect partial duplications and deletions for all autosomes and aneuploidy status for all chromosomes. The test offers an option to request the reporting of sex chromosome aneuploidy (SCA). This product must not be used as the sole basis for diagnosis or other pregnancy management decisions.
Limitations of the test
Noninvasive prenatal testing (NIPT) based on cell-free DNA analysis from maternal blood is a screening test; it is not diagnostic. False positive and false negative results do occur. Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision. A negative result does not eliminate the possibility that the pregnancy has a chromosomal or sub chromosomal abnormality. This test does not screen for polyploidy (eg, triploidy), birth defects such as open neural tube defects, single gene disorders, or other conditions, such as autism. There is a small possibility that the test results might not reflect the chromosomal status of the fetus, but may instead reflect chromosomal changes in the placenta (confined placental mosaicism, CPM) or the mother that may or may not have clinical significance.